1887

Chapter 11 : Antiretroviral Agents

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Antiretroviral Agents, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815981/9781555814250_Chap11-1.gif /docserver/preview/fulltext/10.1128/9781555815981/9781555814250_Chap11-2.gif

Abstract:

In 1987, zidovudine became the first approved agent in the United States for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Two decades later, 24 additional agents in six drug classes had been approved. These include nucleoside analog reverse transcriptase inhibitors (NRTIs), a nucleotide analog reverse transcriptase inhibitor, nonnucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors, and an integrase inhibitor. This chapter describes the major characteristics of antiretroviral agents that are currently approved, or at a promising stage of development, and is organized according to the virus replication cycle. The current therapeutic niche of chemokine receptor 5 (CCR5) inhibitors is as one component of combination regimens for patients with multidrug-resistant R5 virus. In vitro, maraviroc demonstrates no antagonism with existing antiretroviral agents and additive or synergistic activity in combination with enfuvirtide. Vicriviroc is a potent inhibitor of most R5 viruses in vitro, with an IC in the range of 20 nM. It demonstrates additive or synergistic activity in combination with other approved antiretroviral agents. Additive or synergistic in vitro inhibition has been reported with double or triple combinations of numerous antiretroviral agents, except for zidovudine-stavudine, which is an antagonistic combination. Stavudine enjoys relatively few drug-drug interactions compared to other antiretroviral agents. The major mechanism of clearance of raltegravir in humans is by hepatic uridine diphosphoglucuronosyl transferase (UGT)-1A1. Amprenavir is additive with a number of other antiretroviral agents (zidovudine, didanosine, abacavir, saquinavir, indinavir, and ritonavir).

Citation: Sobieszczyk M, Taylor B, Hammer S. 2009. Antiretroviral Agents, p 167-216. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch11

Key Concept Ranking

Reverse Transcriptase Inhibitors
1.2291145
Protease Inhibitors
0.83023715
Integrase Inhibitors
0.8118673
Human immunodeficiency virus 1
0.46831062
1.2291145
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Replication cycle of HIV-1 with current targets for antiretroviral therapy. (Adapted from reference with permission [http://clinicaloptions.com/hiventry].)

Citation: Sobieszczyk M, Taylor B, Hammer S. 2009. Antiretroviral Agents, p 167-216. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch11
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

Chemical structures of entry inhibitors.

Citation: Sobieszczyk M, Taylor B, Hammer S. 2009. Antiretroviral Agents, p 167-216. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch11
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 3
FIGURE 3

Chemical structures of NRTIs.

Citation: Sobieszczyk M, Taylor B, Hammer S. 2009. Antiretroviral Agents, p 167-216. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch11
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 4
FIGURE 4

Chemical structures of NNRTIs.

Citation: Sobieszczyk M, Taylor B, Hammer S. 2009. Antiretroviral Agents, p 167-216. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch11
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 5
FIGURE 5

Chemical structures of PIs.

Citation: Sobieszczyk M, Taylor B, Hammer S. 2009. Antiretroviral Agents, p 167-216. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch11
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555815981.ch11
1. Ananworanich, J.,, A. Hill,, U. Siangphoe,, K. Ruxrungtham,, W. Prasithsirikul,, P. Chetchotisakd,, S. Kiertiburanakul,, W. Munsakul,, P. Raksakulkarn,, S. Tansuphasawadikul,, R. Nuesch,, D. A. Cooper, and, B. Hirschel. 2005. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. Antivir. Ther. 10:761767.
2. Arenzana-Seisdedos, F.,, J. L. Virelizier,, D. Rousset,, I. Clark-Lewis,, P. Loetscher,, B. Moser, and, M. Baggiolini. 1996. HIV blocked by chemokine antagonist. Nature 383:400.
3. Arnaiz, J. A.,, J. Mallolas,, D. Podzamczer,, J. Gerstoft,, J. D. Lundgren,, P. Cahn,, G. Fatkenheuer,, A. D’Arminio-Monforte,, A. Casiro,, P. Reiss,, D. M. Burger,, M. Stek, and, J. M. Gatell. 2003. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS 17:831840.
4. Reference deleted.
5. Arribas, J. R.,, A. L. Pozniak,, J. E. Gallant,, E. Dejesus,, B. Gazzard,, R. E. Campo,, S. S. Chen,, D. McColl,, C. B. Holmes,, J. Enejosa,, J. J. Toole, and, A. K. Cheng. 2008. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J. Acquir. Immune Defic. Syndr. 47:7478.
6. Avinhingsanon, A.,, W. Monsuthi,, P. Kantipong,, C. Chuchotaworn,, S. Moolphate,, N. Yamada,, H. Yanai,, P. Phanuphak,, D. Burger, and, K. Ruxrungtham. 2007. Pharmacokinetics and 12 weeks efficacy of nevirapine 600 mg per day in HIV infected patients with active TB receiving rifampicin: a multicenter study, abstr. 576. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
7. Back, D.,, V. Sekar, and, R. M. Hoetelmans. 2008. Darunavir: pharmacokinetics and drug interactions. Antivir. Ther. 13:113.
8. Baxter, J. D.,, J. M. Schapiro,, C. A. Boucher,, V. M. Kohlbrenner,, D. B. Hall,, J. R. Scherer, and, D. L. Mayers. 2006. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J. Virol. 80:1079410801.
9. Benson, C. A.,, S. G. Deeks,, S. C. Brun,, R. M. Gulick,, J. J. Eron,, H. A. Kessler,, R. L. Murphy,, C. Hicks,, M. King,, D. Wheeler,, J. Feinberg,, R. Stryker,, P. E. Sax,, S. Riddler,, M. Thompson,, K. Real,, A. Hsu,, D. Kempf,, A. J. Japour, and, E. Sun. 2002. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J. Infect. Dis. 185:599607.
10. Berenguer, J.,, B. Padilla,, V. Estrada,, C. Martin,, P. Domingo,, J. M. Kindelán, and, J. M. Ruiz-Guiardin. 2002. Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug. AIDS 16:12991301.
11. Blum, M. R.,, S. H. Liao,, S. S. Good, and, P. de Miranda. 1988. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85:189194.
12. Bongiovanni, M.,, T. Bini,, F. Adorni,, P. Meraviglia,, A. Capetti,, F. Tordato,, P. Cicconi,, E. Chiesa,, L. Cordier,, A. Cargnel,, S. Landonio,, S. Rusconi, and, A. d’Arminio Monforte. 2003. Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations. Antivir. Ther. 8:209214.
13. Borin, M. T.,, J. H. Chambers,, B. J. Carel,, W. W. Freimuth,, S. Aksentijevich, and, A. A. Piergies. 1997. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antivir. Res. 35:5363.
14. Boubaker, K.,, M. Flepp,, P. Sudre,, H. Furrer,, A. Haensel,, B. Hirschel,, K. Boggian,, J. P. Chave,, E. Bernasconi,, M. Egger,, M. Opravil,, M. Rickenbach,, P. Francioli, and, A. Telenti. 2001. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin. Infect. Dis. 33:19311937.
15. Boucher, C. A.,, N. Cammack,, P. Schipper,, R. Schuurman,, P. Rouse,, M. A. Wainberg, and, J. M. Cameron. 1993. High-level resistance to (–) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:22312234.
16. Boyd, M.,, C. Duncombe,, K. Ruxrungthram,, M. Khongphattanayothin,, E. Hassink,, P. Srasuebkul,, J. Sangkote,, P. Reiss,, M. Stek,, J. Lange,, D. A. Cooper, and, P. Phanuphak. 2002. Indinavir TID vs indinavir/ritonavir BID in combination with AZT/3TC for HIV infection in nucleoside pretreated patients: HIV-NAT 005 76-week follow up, abstr. 422-W. 9th Conf. Retrovir. Opportunistic Infect., Seattle, WA.
17. Brehm, J.,, D. Koontz,, S. Zelina,, N. Sluis-Cremer, and, J. Mellors. 2007. 3′-Azido-3′-dideoxythymidine selects mutations in the connection (A371V) and RNase H (Q509L) domains of reverse transcriptase that increase AZT resistance in combination with thymidine analog mutations without affecting the rate of AZT excision on a DNA/DNA template/primer, abstr. 90. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
18. Brown, T. T.,, S. R. Cole,, X. Li,, L. A. Kingsley,, F. J. Palella,, S. A. Riddler,, B. R. Visscher,, J. B. Margolick, and, A. S. Dobs. 2005. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch. Intern. Med. 165:11791184.
19. Cahn, P.,, R. Haubrich,, J. Leider,, G. Pialoux,, M. Schechter,, S. Walmsley,, J. Vingerhoets,, M. Peeters,, G. De Smedt,, M. P. de Béthune, and, B. Woodfall. 2007. Pooled 24-week results of DUET-1 and -2: TMC125 (etravirine; ETR) vs placebo in 1203 treatment-experienced HIV-1-infected patients, abstr. H-717. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
20. Calza, L.,, R. Manfredi,, B. Farneti, and, F. Chiodo. 2003. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. Int. J. Antimicrob. Agents 22:5459.
21. Campo, R.,, B. da Silva,, L. Cotte,, J Gathe,, B. Gazzard,, C. Hicks,, M. Dehaan,, K. Wikstrom,, M. King, and, G. Hanna. 2007. Predictors of loss of virologic response in subjects who deintensified to lopinavir/ritonavir monotherapy after achieving plasma HIV-1 RNA <50 copies/mL on LPV/r plus zidovudine/lamivudine, abstr. 514. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
22. Cardo, D. M.,, D. H. Culver,, C. A. Ciesielski,, P. U. Srivastava,, R. Marcus,, D. Abiteboul,, J. Heptonstall,, G. Ippolito,, F. Lot,, P. S. McKibben, and, D. M. Bell for The Centers for Disease Control and Prevention Needlestick Surveillance Group. 1997. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N. Engl. J. Med. 337:14851490.
23. Carr, A. 2003. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 17(Suppl. 1):S141S148.
24. Carr, A. 2000. HIV protease inhibitor-related lipodystrophy syndrome. Clin. Infect. Dis. 30(Suppl. 2):S135S142.
25. Carr, A.,, and D. A. Cooper. 2000. Adverse effects of antiretroviral therapy. Lancet 356:14231430.
26. Ceccherini-Silberstein, F.,, V. Svicher,, T. Sing,, A. Artese,, M. M. Santoro,, F. Forbici,, A. Bertoli,, S. Alcaro,, G. Palamara,, A. d’Arminio Monforte,, J. Balzarini,, A. Antinori,, T. Lengauer, and, C. F. Perno. 2007. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. J. Virol. 81:1150711519.
27. Cepeda, J. A.,, and D. Wilks. 2000. Excess peripheral neuropathy in patients treated with hydroxyurea plus didanosine and stavudine for HIV infection. AIDS 14:332333.
28. Chamberlain, P. P.,, J. Ren,, C. E. Nichols,, L. Douglas,, J. Lennerstrand,, B. A. Larder,, D. I. Stuart, and, D. K. Stammers. 2002. Crystal structures of zidovudine- or lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215. J. Virol. 76:1001510019.
29. Chan-Tack, K. M.,, M. M. Truffa,, K. A. Struble, and, D. B. Birnkrant. 2007. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration’s Adverse Event Reporting System. AIDS 21:12151218.
30. Chi, B. H.,, M. Sinkala,, F. Mbewe,, R. A. Cantrell,, G. Kruse,, N. Chintu,, G. M. Aldrovandi,, E. M. Stringer,, C. Kankasa,, J. T. Safrit, and, J. S. Stringer. 2007. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 370:16981705.
31. Clarke, S. M.,, F. M. Mulcahy,, J. Tjia,, H. E. Reynolds,, S. E. Gibbons,, M. G. Barry, and, D. J. Back. 2001. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin. Infect. Dis. 33:15951597.
32. Clarke, S. M.,, F. M. Mulcahy,, J. Tjia,, H. E. Reynolds,, S. E. Gibbons,, M. G. Barry, and, D. J. Back. 2001. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br. J. Clin. Pharmacol. 51:213217.
33. Clavel, F.,, and A. J. Hance. 2004. HIV drug resistance. N. Engl. J. Med. 350:10231035.
34. Clotet, B.,, N. Bellos,, J. M. Molina,, D. Cooper,, J. C. Goffard,, A. Lazzarin,, A. Wohrmann,, C. Katlama,, T. Wilkin,, R. Haubrich,, C. Cohen,, C. Farthing,, D. Jayaweera,, M. Markowitz,, P. Ruane,, S. Spinosa-Guzman, and, E. Lefebvre. 2007. Efficacy and safety of darunavirritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369:11691178.
35. Clumeck, N.,, F. Goebel,, W. Rozenbaum,, J. Gerstoft,, S. Staszewski,, J. Montaner,, M. Johnson,, B. Gazzard,, C. Stone,, R. Athisegaran, and, S. Moore. 2001. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 15:15171526.
36. Coghlan, M. E.,, J. P. Sommadossi,, N. C. Jhala,, W. J. Many,, M. S. Saag, and, V. A. Johnson. 2001. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin. Infect. Dis. 33:19141921.
37. Condra, J. H.,, W. A. Schleif,, O. M. Blahy,, L. J. Gabryelski,, D. J. Graham,, J. C. Quintero,, A. Rhodes,, H. L. Robbins,, E. Roth,, M. Shivaprakash,, D. Titus,, T. Yang,, H. Tepplert,, K. E. Squires,, P. J. Deutsch, and, E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569571.
38. Connor, E. M.,, R. S. Sperling,, R. Gelber,, P. Kiselev,, G. Scott,, M. J. O’Sullivan,, R. VanDyke,, M. Bey,, W. Shearer,, R. L. Jacobson,, E. Jimenez,, E. O’Neill,, B. Bazin,, J.-F. Delfraissy,, M. Culnane,, R. Coombs,, M. Elkins,, J. Moye,, P. Stratton, and, J. Balsley for The Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N. Engl. J. Med. 331:11731180.
39. Cooper, D.,, J. G.,, J. Rockstroh,, C. Katlama,, P. Yeni,, A. Lazzarin,, X. Xu,, R. Isaacs,, H. Teppler, and, B. Y. Nguyen. 2008. 48-Week results from BENCHMRK-1, a phase III study of raltegravir in patients failing ART with triple-class resistant HIV-1, abstr. 788. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.
40. Cressey, T. R.,, H. Green,, S. Khoo,, J. M. Treluyer,, A. Compagnucci,, Y. Saidi,, M. Lallemant,, D. M. Gibb, and, D. M. Burger. 2008. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children. Clin. Infect. Dis. 46:16011608.
41. Cui, L.,, R. F. Schinazi,, G. Gosselin,, J. L. Imbach,, C. K. Chu,, R. F. Rando,, G. R. Revankar, and, J. P. Sommadossi. 1996. Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity. Biochem. Pharmacol. 52:15771584.
42. Das, K.,, A. D. Clark, Jr.,, P. J. Lewi,, J. Heeres,, M. R. De Jonge,, L. M. Koymans,, H. M. Vinkers,, F. Daeyaert,, D. W. Ludovici,, M. J. Kukla,, B. De Corte,, R. W. Kavash,, C. Y. Ho,, H. Ye,, M. A. Lichtenstein,, K. Andries,, R. Pauwels,, M. P. De Bethune,, P. L. Boyer,, P. Clark,, S. H. Hughes,, P. A. Janssen, and, E. Arnold. 2004. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47:25502560.
43. De Clercq, E. 2007. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov. 6:10011018.
44. DeJesus, E.,, D. Berger,, M. Markowitz,, C. Cohen,, T. Hawkins,, P. Ruane,, R. Elion,, C. Farthing,, L. Zhong,, A. K. Cheng,, D. McColl, and, B. P. Kearney. 2006. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 43:15.
45. DeJesus, E.,, G. Herrera,, E. Teofilo,, J. Gerstoft,, C. B. Buendia,, J. D. Brand,, C. H. Brothers,, J. Hernandez,, S. A. Castillo,, T. Bonny,, E. R. Lanier, and, T. R. Scott. 2004. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin. Infect. Dis. 39:10381046.
46. DeJesus, E.,, S. Walmsley,, C. Cohen,, D. Cooper,, B. Hirschel,, J. Goodrich,, H. Valdez,, J. Heera,, N. Rajicic, and, N. Maye. 2008. Fasted lipid changes after administration of maraviroc or efavirenz in combination with zidovudine and lamivudine for 48 weeks to treatment-naïve HIV-infected patients, abstr. 929. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.
47. Delaunay, C.,, F. Brun-Vezinet,, R. Landman,, G. Collin,, G. Peytavin,, A. Trylesinski,, P. Flandre,, M. Miller, and, D. Descamps. 2005. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J. Virol. 79:95729578.
48. Delehanty, J.,, C. Wakeford,, L. Hulett,, J. Quinn,, B. McCreedy,, M. Almond,, D. Miralles,, F. Rousseau. 1999. A phase I/II randomized, controlled study of FTC versus 3TC in HIV-infected patients, abstr. 16. 6th Conf. Retrovir. Opportunistic Infect., Chicago, IL.
49. Derdeyn, C. A.,, J. M. Decker,, J. N. Sfakianos,, X. Wu,, W. A. O’Brien,, L. Ratner,, J. C. Kappes,, G. M. Shaw, and, E. Hunter. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:83588367.
50. Descamps, D.,, V. Joly,, P. Flandre,, G. Peytavin,, V. Meiffredy,, S. Delarue,, S. Lastere,, J. P. Aboulker,, P. Yeni, and, F. Brun-Vezinet. 2005. Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial (Novavir ANRS 073). J. Clin. Virol. 33:99103.
51. Doms, R. W. 5 October 2007, posting date. Understanding HIV entry and targets for therapy. Clinical Care Options HIV. Clinical Care Options, Reston, VA. http://clinicaloptions.com/hiventry.
52. Dorr, P.,, M. Westby,, S. Dobbs,, P. Griffin,, B. Irvine,, M. Macartney,, J. Mori,, G. Rickett,, C. Smith-Burchnell,, C. Napier,, R. Webster,, D. Armour,, D. Price,, B. Stammen,, A. Wood, and, M. Perros. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:47214732.
53. Dragic, T.,, V. Litwin,, G. P. Allaway,, S. R. Martin,, Y. Huang,, K. A. Nagashima,, C. Cayanan,, P. J. Maddon,, R. A. Koup,, J. P. Moore, and, W. A. Paxton. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667673.
54. Dragsted, U. B.,, J. Gerstoft,, C. Pedersen,, B. Peters,, A. Duran,, N. Obel,, A. Castagna,, P. Cahn,, N. Clumeck,, J. N. Bruun,, J. Benetucci,, A. Hill,, I. Cassetti,, P. Vernazza,, M. Youle,, Z. Fox, and, J. D. Lundgren. 2003. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J. Infect. Dis. 188:635642.
55. Dronda, F.,, J. L. Casado,, S. Moreno,, K. Hertogs,, I. Garcia-Arata,, A. Antela,, M. J. Perez-Elias,, L. Ruiz, and, B. Larder. 2001. Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene. AIDS Res. Hum. Retrovir. 17:211215.
56. Dudley, M. N. 1995. Clinical pharmacokinetics of nucleoside antiretroviral agents. J. Infect. Dis. 171(Suppl. 2):S99S112.
57. Dufer, M.,, Y. Neye,, P. Krippeit-Drews, and, G. Drews. 2004. Direct interference of HIV protease inhibitors with pancreatic beta-cell function. Naunyn-Schmiedeberg’s Arch. Pharmacol. 369:583590.
58. Elston, R.,, J. Scherer,, D. Hall,, J. Schapiro,, R. Bethell,, V. Kohlbrenner, and, D. Mayers. 2006. De-selection of the I50V mutation occurs in clinical isolates during aptivus/r (tipranavir/ritonavir)-based therapy, abstr. 92. 15th Int. HIV Drug Resistance Workshop, Sitges, Spain.
59. Elston, R. C.,, D. R. Kuritzkes, and, R. Bethell. 2007. An investigation into the influence of the tipranavir-associated V82L/T mutations on the susceptibility to darunavir and brecanavir, abstr. 602. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
60. Eron, J.,, Jr., P. Yeni,, J. Gathe,, Jr., V. Estrada,, E. DeJesus,, S. Staszewski,, P. Lackey,, C. Katlama,, B. Young,, L. Yau,, D. Sutherland-Phillips,, P. Wannamaker,, C. Vavro,, L. Patel,, J. Yeo, and, M. Shaefer. 2006. The KLEAN study of fosamprenavir-ritonavir versus lopinavirritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 368:476482.
61. Eron, J. J.,, Jr., R. L. Murphy,, D. Peterson,, J. Pottage,, D. M. Parenti,, J. Jemsek,, S. Swindells,, G. Sepulveda,, N. Bellos,, B. C. Rashbaum,, J. Esinhart,, N. Schoellkopf,, R. Grosso, and, M. Stevens. 2000. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS 14:16011610.
62. Eshleman, S. H.,, D. R. Hoover,, S. Chen,, S. E. Hudelson,, L. A. Guay,, A. Mwatha,, S. A. Fiscus,, F. Mmiro,, P. Musoke,, J. B. Jackson,, N. Kumwenda, and, T. Taha. 2005. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 19:21672169.
63. Feng, J. Y.,, J. Shi,, R. F. Schinazi, and, K. S. Anderson. 1999. Mechanistic studies show that (–)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TCTP. FASEB J. 13:15111517.
64. Fischl, M.,, B. Young,, M. Watkins,, R. Arduino,, E. Jensen,, H. Wilson,, C. Carey,, A. Desai, and, J. Schranz. 2001. Direct study: a multicenter, open-label, 24-wk pilot study with a 24-wk extension to evaluate the safety, tolerability and efficacy of indinavir (IDV)-ritonavir (RTV) 800/100 bid in combination with D4T plus 3TC in HIV-infected individuals (Merck Protocol 094), abstr. I-1923. 41st Intersci. Conf. Antimicrob. Agents Chemother.
65. Friedland, G.,, S. Khoo,, C. Jack, and, U. Lalloo. 2006. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J. Antimicrob. Chemother. 58:12991302.
66. Friedland, G. H.,, R. Pollard,, B. Griffith,, M. Hughes,, G. Morse,, R. Bassett,, W. Freimuth,, L. Demeter,, E. Connick,, T. Nevin,, M. Hirsch, and, M. Fischl for the ACTG 261 Team. 1999. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). J. Acquir. Immune Defic. Syndr. 21:281292.
67. Friend, J.,, N. Parkin,, T. Liegler,, J. N. Martin, and, S. G. Deeks. 2004. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 18:19651966.
68. Fundaro, C.,, O. Genovese,, C. Rendeli,, E. Tamburrini, and, E. Salvaggio. 2002. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 16:299300.
69. Gallant, J.,, A. Pozniak,, E. DeJesus,, J. Arribas,, R. Campo,, S.-S. Chen,, D. McColl,, J. Enejosa, and, A. Cheng. 2006. Efficacy and safety of tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV through 96 weeks in antiretroviral treatment-naïve patients, abstr. TUPE0064. XVI Int. AIDS Conf., Toronto, Canada.
70. Gallant, J. E.,, E. DeJesus,, J. R. Arribas,, A. L. Pozniak,, B. Gazzard,, R. E. Campo,, B. Lu,, D. McColl,, S. Chuck,, J. Enejosa,, J. J. Toole, and, A. K. Cheng. 2006. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 354:251260.
71. Gallant, J. E.,, M. A. Parish,, J. C. Keruly, and, R. D. Moore. 2005. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin. Infect. Dis. 40:11941198.
72. Gallant, J. E.,, S. Staszewski,, A. L. Pozniak,, E. DeJesus,, J. M. Suleiman,, M. D. Miller,, D. F. Coakley,, B. Lu,, J. J. Toole, and, A. K. Cheng. 2004. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292:191201.
73. Gathe, J. C.,, Jr., P. Ive,, R. Wood,, D. Schurmann,, N. C. Bellos,, E. DeJesus,, A. Gladysz,, C. Garris, and, J. Yeo. 2004. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 18:15291537.
74. Gazzard, B. G.,, A. L. Pozniak,, W. Rosenbaum,, G. P. Yeni,, S. Staszewski,, K. Arasteh,, K. De Dier,, M. Peeters,, B. Woodfall,, J. Stebbing, and, G. A. vant’ Klooster. 2003. An open-label assessment of TMC 125—a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 17:F49F54.
75. Goebel, F.,, A. Yakovlev,, A. L. Pozniak,, E. Vinogradova,, G. Boogaerts,, R. Hoetelmans,, M. P. de Bethune,, M. Peeters, and, B. Woodfall. 2006. Short-term antiviral activity of TMC278—a novel NNRTI—in treatment-naive HIV-1-infected subjects. AIDS 20:17211726.
76. Gotte, M.,, D. Arion,, M. A. Parniak, and, M. A. Wainberg. 2000. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J. Virol. 74:35793585.
77. Graff, J.,, N. von Hentig,, K. Kuczka,, C. Angioni,, P. Gute,, S. Klauke,, E. Babacan, and, S. Harder. 2008. Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo. J. Antimicrob. Chemother. 61:394399.
78. Grinsztejn, B.,, B. Y. Nguyen,, C. Katlama,, J. M. Gatell,, A. Lazzarin,, D. Vittecoq,, C. J. Gonzalez,, J. Chen,, C. M. Harvey, and, R. D. Isaacs. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369:12611269.
79. Gruzdev, B.,, A. Rakhmanova,, E. Doubovskaya,, A. Yakovlev,, M. Peeters,, A. Rinehart,, K. de Dier,, P. Baede-Van Dijk,, W. Parys, and, G. van’t Klooster. 2003. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS 17:24872494.
80. Guillemi, S.,, F. Ng,, W. Zhang,, V. Lima,, C. Rocha,, M. Harris,, G. Bondy,, A. Belzberg, and, J. Montaner. 2008. Risk factors for reduced bone mineral density in HIV-infected individuals in the modern HAART era, abstr. 969. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.
81. Gulick, R. M.,, X. J. Hu,, S. A. Fiscus,, C. V. Fletcher,, R. Haubrich,, H. Cheng,, E. Acosta,, S. W. Lagakos,, R. Swanstrom,, W. Freimuth,, S. Snyder,, C. Mills,, M. Fischl,, C. Pettinelli, and, D. Katzenstein. 2002. Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. J. Infect. Dis. 186:626633.
82. Gulick, R. M.,, X. J. Hu,, S. A. Fiscus,, C. V. Fletcher,, R. Haubrich,, H. Cheng,, E. Acosta,, S. W. Lagakos,, R. Swanstrom,, W. Freimuth,, S. Snyder,, C. Mills,, M. Fischl,, C. Pettinelli, and, D. Katzenstein. 2000. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J. Infect. Dis. 182:13751384.
83. Gulick, R. M.,, H. J. Ribaudo,, C. M. Shikuma,, C. Lalama,, B. R. Schackman,, W. A. Meyer III,, E. P. Acosta,, J. Schouten,, K. E. Squires,, C. D. Pilcher,, R. L. Murphy,, S. L. Koletar,, M. Carlson,, R. C. Reichman,, B. Bastow,, K. L. Klingman, and, D. R. Kuritzkes. 2006. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 296:769781.
84. Gulick, R. M.,, H. J. Ribaudo,, C. M. Shikuma,, S. Lustgarten,, K. E. Squires,, W. A. Meyer III,, E. P. Acosta,, B. R. Schackman,, C. D. Pilcher,, R. L. Murphy,, W. E. Maher,, M. D. Witt,, R. C. Reichman,, S. Snyder,, K. L. Klingman, and, D. R. Kuritzkes. 2004. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. 350:18501861.
85. Gulick, R. M.,, Z. Su,, C. Flexner,, M. D. Hughes,, P. R. Skolnik,, T. J. Wilkin,, R. Gross,, A. Krambrink,, E. Coakley,, W. L. Greaves,, A. Zolopa,, R. Reichman,, C. Godfrey,, M. Hirsch, and, D. R. Kuritzkes for the AIDS Clinical Trials Group 5211 Team. 2007. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J. Infect. Dis. 196:304312.
86. Haas, D. W.,, B. Johnson,, J. Nicotera,, V. L. Bailey,, V. L. Harris,, F. B. Bowles,, S. Raffanti,, J. Schranz,, T. S. Finn,, A. J. Saah, and, J. Stone. 2003. Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma. Antimicrob. Agents Chemother. 47:21312137.
87. Hammer, S. M.,, M. S. Saag,, M. Schechter,, J. S. Montaner,, R. T. Schooley,, D. M. Jacobsen,, M. A. Thompson,, C. C. Carpenter,, M. A. Fischl,, B. G. Gazzard,, J. M. Gatell,, M. S. Hirsch,, D. A. Katzenstein,, D. D. Richman,, S. Vella,, P. G. Yeni, and, P. A. Volberding. 2006. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society—USA panel. Top. HIV Med 14:827843.
88. Hanna, G. J.,, V. A. Johnson,, D. R. Kuritzkes,, D. D. Richman,, A. J. Brown,, A. V. Savara,, J. D. Hazelwood, and, R. T. D’Aquila. 2000. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J. Infect. Dis. 181:904911.
89. Harrigan, P. R.,, C. Stone,, P. Griffin,, I. Nájera,, S. Bloor,, S. Kemp,, M. Tisdale,, B. Larder, and the CNA2001 Investigative Group. 2000. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. J. Infect. Dis. 181:912920.
90. Hartt, J. K.,, T. Liang,, A. Sahagun-Ruiz,, J. M. Wang,, J. L. Gao, and, P. M. Murphy. 2000. The HIV-1 cell entry inhibitor T-20 potently chemoattracts neutrophils by specifically activating the N-formylpeptide receptor. Biochem. Biophys. Res. Commun. 272:699704.
91. Haubrich, R.,, D. Berger,, P. Chiliade,, A. Colson,, M. Conant,, J. Gallant,, T. Wilkin,, J. Nadler,, G. Pierone,, M. Saag,, B. van Baelen, and, E. Lefebvre. 2007. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 21:F11F18.
92. Haubrich, R.,, P. Cahn,, B. Grinsztejn,, J. Lalezari,, J. Madruga,, A. Mills,, M. Peeters,, J. Vingerhoets,, K. Iveson, and, G. De Smedt. 2008. DUET-1: week 48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 612 treatment-experienced HIV-1-infected patients, abstr. 790. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.
93. Haubrich, R. H.,, S. Riddler,, G. DiRienzo,, L. Komarow,, W. Powderly,, K. Garren,, T. George,, J. Rooney,, J. Mellors, and, D. Havlir. 2007. Metabolic outcomes of ACTG 5142: a prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection, abstr. 38. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
94. Hazuda, D. J.,, P. Felock,, M. Witmer,, A. Wolfe,, K. Stillmock,, J. A. Grobler,, A. Espeseth,, L. Gabryelski,, W. Schleif,, C. Blau, and, M. D. Miller. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646650.
95. Hazuda, D. J.,, S. D. Young,, J. P. Guare,, N. J. Anthony,, R. P. Gomez,, J. S. Wai,, J. P. Vacca,, L. Handt,, S. L. Motzel,, H. J. Klein,, G. Dornadula,, R. M. Danovich,, M. V. Witmer,, K. A. Wilson,, L. Tussey,, W. A. Schleif,, L. S. Gabryelski,, L. Jin,, M. D. Miller,, D. R. Casimiro,, E. A. Emini, and, J. W. Shiver. 2004. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305:528532.
96. Heera, J.,, M. Saag,, P. Ive,, J. Whitcomb,, M. Lewis,, L. McFadyen,, J. Goodrich,, H. Mayer,, E. van der Ryst, and, M. Westby. 2008. Virological correlates associated with treatment failure at week 48 in the phase 3 study of maraviroc in treatment-naive patients, abstr. 40LB. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.
97. Hertogs, K.,, S. Bloor,, S. D. Kemp,, C. Van den Eynde,, T. M. Alcorn,, R. Pauwels,, M. Van Houtte,, S. Staszewski,, V. Miller, and, B. A. Larder. 2000. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 14:12031210.
98. Hicks, C.,, E. DeJesus,, D. Wohl,, Q. Liao,, K. Pappa, and, T. Lancaster. 2007. Once-daily fosamprenavir (FPV) boosted with either 100mg or 200mg of ritonavir (r) along with abacavir (ABC)/lamivudine (3TC): 48 week safety and efficacy results from COL100758. 11th Eur. AIDS Conf., Madrid, Spain.
99. Hicks, C. B.,, P. Cahn,, D. A. Cooper,, S. L. Walmsley,, C. Katlama,, B. Clotet,, A. Lazzarin,, M. A. Johnson,, D. Neubacher,, D. Mayers, and, H. Valdez. 2006. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 368:466475.
100. Hu, Z.,, F. Giguel,, H. Hatano,, P. Reid,, J. Lu, and, D. R. Kuritzkes. 2006. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J. Virol. 80:70207027.
101. Hunt, P. W.,, P. R. Harrigan,, W. Huang,, M. Bates,, D. W. Williamson,, J. M. McCune,, R. W. Price,, S. S. Spudich,, H. Lampiris,, R. Hoh,, T. Leigler,, J. N. Martin, and, S. G. Deeks. 2006. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J. Infect. Dis. 194:926930.
102. Iversen, A. K.,, R. W. Shafer,, K. Wehrly,, M. A. Winters,, J. I. Mullins,, B. Chesebro, and, T. C. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:10861090.
103. Ives, K. J.,, H. Jacobsen,, S. A. Galpin,, M. M. Garaev,, L. Dorrell,, J. Mous,, K. Bragman, and, J. N. Weber. 1997. Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. J. Antimicrob. Chemother. 39:771779.
104. Iwamoto, M.,, L. A. Wenning,, G. C. Mistry,, A. S. Petry,, S. Y. Liou,, K. Ghosh,, S. Breidinger,, N. Azrolan,, M. J. Gutierrez,, W. E. Bridson,, J. A. Stone,, K. M. Gottesdiener, and, J. A. Wagner. 2008. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin. Infect. Dis. 47:137140.
105. Iwamoto, M.,, L. A. Wenning,, A. S. Petry,, T. Laethem,, M. Desmet,, J. T. Kost,, S. Merschman,, E. Mangin,, N. Azrolan,, H. E. Greenberg,, W. Haazen,, J. A. Stone,, K. M. Gottesdiener, and, J. A. Wagner. 2006. Minimal effect of ritonavir (RTV) and efavirenz (EFV) on the pharmacokinetics (PK) of Mk-0518, abstr. A-373. 46th Intersci. Conf. Antimicrob. Agents Chemother.
106. Jacobsen, H.,, K. Yasargil,, D. L. Winslow,, J. C. Craig,, A. Krohn,, I. B. Duncan, and, J. Mous. 1995. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206:527534.
107. Johnson, M.,, B. Grinsztejn,, C. Rodriguez,, J. Coco,, E. DeJesus,, A. Lazzarin,, K. Lichtenstein,, V. Wirtz,, A. Rightmire,, L. Odeshoo, and, C. McLaren. 2006. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 20:711718.
108. Johnson, M.,, T. Campbell,, B. Clotet,, C. Katlama,, A. Lazzarin,, W. Towner,, M. Peeters,, J. Vingerhoets,, S. Bollen, and, G. De Smedt. 2008. DUET-2: week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1-infected patients, abstr. 791. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.
109. Johnson, M. A.,, J. C. Gathe, Jr.,, D. Podzamczer,, J. M. Molina,, C. T. Naylor,, Y. L. Chiu,, M. S. King,, T. J. Podsadecki,, G. J. Hanna, and, S. C. Brun. 2006. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J. Acquir. Immune Defic. Syndr. 43:153160.
110. Johnson, V. A.,, F. Brun-Vezinet,, B. Clotet,, H. F. Gunthard,, D. R. Kuritzkes,, D. Pillay,, J. M. Schapiro, and, D. D. Richman. 2007. Update of the drug resistance mutations in HIV-1: 2007. Top. HIV Med. 15:119125.
111. Johnson, V. A.,, F. Brun-Vezinet,, B. Clotet,, H. F. Gunthard,, D. R. Kuritzkes,, D. Pillay,, J. M. Schapiro, and, D. D. Richman. 2008. Update of the drug resistance mutations in HIV-1: spring 2008. Top. HIV Med. 16:6268.
112. Joly, V.,, P. Flandre,, V. Meiffredy,, N. Leturque,, M. Harel,, J. P. Aboulker, and, P. Yeni. 2002. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 16:24472454.
113. Joly, V.,, M. Moroni,, E. Concia,, A. Lazzarin,, B. Hirschel,, J. Jost,, F. Chiodo,, Z. Bentwich,, W. C. Love,, D. A. Hawkins,, E. G. L. Wilkins,, A. J. Gatell,, N. Vetter,, C. Greenwald,, W. W. Freimuth,, W. de Cian, and The M/3331/0013B Study Group. 2000. Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. Antimicrob. Agents Chemother. 44:31553157.
114. Kagan, R. M.,, M. D. Shenderovich,, P. N. Heseltine, and, K. Ramnarayan. 2005. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir. Protein Sci. 14:18701878.
115. Kakuda, T. 2000. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. 22:685708.
116. Kassahun, K.,, I. McIntosh,, D. Cui,, D. Hreniuk,, S. Merschman,, K. Lasseter,, N. Azrolan,, M. Iwamoto,, J. A. Wagner, and, L. A. Wenning. 2007. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos. 35:16571663.
117. Katlama, C.,, T. Campbell,, B. Clotet,, M. Johnson,, A. Lazzarin,, K. Arasteh,, W. Towner,, B. Trottier,, M. Peeters,, J. Vingerhoets,, G. De Smedt,, B. Baeten,, G. Beets,, R. Sinha, and, B. Woodfall. 2007. DUET-2: 24-week results of a phase III randomised double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1 infected patients, abstr. WESS204-2. 4th IAS Conf. HIV Pathog. Treatment Prev., Sydney, Australia.
118. Kearney, B.,, R. Price,, L. Sheiner,, E. Bellibas,, S. Staprans,, L. Thevanayagam, and, F. Aweeka. 1999. Estimation of nevirapine exposure within the cerebrospinal fluid using CSF: plasma area under the curve ratios, abstr. 406. Program Abstr. 6th Conf. Retrovir. Opportunistic Infect., Chicago, IL.
119. Kellam, P.,, C. A. Boucher, and, B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89:19341938.
120. Kempf, D. J.,, J. D. Isaacson,, M. S. King,, S. C. Brun,, J. Sylte,, B. Richards,, B. Bernstein,, R. Rode, and, E. Sun. 2002. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir. Ther. 7:165174.
121. Kempf, D. J.,, J. D. Isaacson,, M. S. King,, S. C. Brun,, Y. Xu,, K. Real,, B. M. Bernstein,, A. J. Japour,, E. Sun, and, R. A. Rode. 2001. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75:74627469.
122. Khanlou, H.,, V. Yeh,, B. Guyer, and, C. Farthing. 2005. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDS 19:135140.
123. Kim, E. Y.,, L. Vrang,, B. Oberg, and, T. C. Merigan. 2001. Anti-HIV type 1 activity of 3′-fluoro-3′-deoxythymidine for several different multidrug-resistant mutants. AIDS Res. Hum. Retrovir. 17:401407.
124. Kindberg, E.,, A. Mickiene,, C. Ax,, B. Akerlind,, S. Vene,, L. Lindquist,, A. Lundkvist, and, L. Svensson. 2008. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J. Infect. Dis. 197:266269.
125. King, M. S.,, R. Rode,, I. Cohen-Codar,, V. Calvez,, A. G. Marcelin,, G. J. Hanna, and, D. J. Kempf. 2007. Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 51:30673074.
126. Kirk, O.,, T. L. Katzenstein,, J. Gerstoft,, L. Mathiesen,, H. Nielsen,, C. Pedersen, and, J. D. Lundgren. 1999. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. AIDS 13:F9F16.
127. Kitchen, V. S.,, C. Skinner,, K. Ariyoshi,, E. A. Lane,, I. B. Duncan,, J. Burckhardt,, H. U. Burger,, K. Bragman,, A. J. Pinching, and, J. N. Weber. 1995. Safety and activity of saquinavir in HIV infection. Lancet 345:952955.
128. Koh, Y.,, T. Towata,, A. Ghosh, and, H. Mitsuya. 2007. Selection in vitro of HIV-1 variants highly resistant to darunavir using a mixture of HIV-1 isolates resistant to multiple PI, abstr. 606. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
129. Kumar, P. N.,, D. E. Sweet,, J. A. McDowell,, W. Symonds,, Y. Lou,, S. Hetherington, and, S. LaFon. 1999. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Antimicrob. Agents Chemother. 43:603608.
130. Kuritzkes, D. R.,, R. L. Bassett,, J. D. Hazelwood,, H. Barrett,, R. A. Rhodes,, R. K. Young, and, V. A. Johnson. 2004. Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. J. Acquir. Immune Defic. Syndr. 36:600603.
131. Lafeuillade, A.,, G. Hittinger, and, S. Chadapaud. 2001. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 357:280281.
132. Lalezari, J. P.,, K. Henry,, M. O’Hearn,, J. S. Montaner,, P. J. Piliero,, B. Trottier,, S. Walmsley,, C. Cohen,, D. R. Kuritzkes,, J. J. Eron, Jr.,, J. Chung,, R. DeMasi,, L. Donatacci,, C. Drobnes,, J. Delehanty, and, M. Salgo. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348:21752185.
133. Landman, R.,, D. Descamps,, G. Peytavin,, A. Trylesinski,, C. Katlama,, P. M. Girard,, B. Bonnet,, P. Yeni,, M. Bentata,, C. Michelet,, A. Benalycherif,, F. Brun Vezinet,, M. D. Miller, and, P. Flandre. 2005. Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study. HIV Clin. Trials 6:291301.
134. Lanier, E. R.,, M. Ait-Khaled,, J. Scott,, C. Stone,, T. Melby,, G. Sturge,, M. St. Clair,, H. Steel,, S. Hetherington,, G. Pearce,, W. Spreen, and, S. Lafon. 2004. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir. Ther. 9:3745.
135. Larder, B. A.,, and S. Boor. 2001. Analysis of clinical isolates and site directed mutants reveals the genetic determinants of didanosine resistance, abstr. 47. 5th Int. Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, AZ.
136. Larder, B. A.,, G. Darby, and, D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:17311734.
137. Larder, B. A.,, K. Hertogs,, S. Bloor,, C. H. van den Eynde,, W. DeCian,, Y. Wang,, W. W. Freimuth, and, G. Tarpley. 2000. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 14:19431948.
138. Larder, B. A.,, S. D. Kemp, and, P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696699.
139. Lazzarin, A.,, T. Campbell,, B. Clotet,, M. Johnson,, C. Katlama,, A. Moll,, W. Towner,, B. Trottier,, M. Peeters,, J. Vingerhoets,, G. de Smedt,, B. Baeten,, G. Beets,, R. Sinha, and, B. Woodfall. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370:3948.
140. Lederman, M. M.,, A. Penn-Nicholson,, M. Cho, and, D. Mosier. 2006. Biology of CCR5 and its role in HIV infection and treatment. JAMA 296:815826.
141. Lim, J. K.,, C. Y. Louie,, C. Glaser,, C. Jean,, B. Johnson,, H. Johnson,, D. H. McDermott, and, P. M. Murphy. 2008. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J. Infect. Dis. 197:262265.
142. Loeliger, A. E.,, H. Steel,, S. McGuirk,, W. S. Powell, and, S. V. Hetherington. 2001. The abacavir hypersensitivity reaction and interruptions in therapy. AIDS 15:13251326.
143. Lu, J.,, S. G. Deeks,, R. Hoh,, G. Beatty,, B. A. Kuritzkes,, J. N. Martin, and, D. R. Kuritzkes. 2006. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J. Acquir. Immune Defic. Syndr. 43:6064.
144. Ly, T.,, and M. E. Ruiz. 2007. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Clin. Infect. Dis. 44:e67e68.
145. MacGregor, T. R.,, J. P. Sabo,, S. H. Norris,, P. Johnson,, L. Galitz, and, S. McCallister. 2004. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin. Trials 5:371382.
146. Madruga, J. V.,, D. Berger,, M. McMurchie,, F. Suter,, D. Banhegyi,, K. Ruxrungtham,, D. Norris,, E. Lefebvre,, M. P. de Bethune,, F. Tomaka,, M. De Pauw,, T. Vangeneugden, and, S. Spinosa-Guzman. 2007. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 370:4958.
147. Madruga, J. V.,, P. Cahn,, B. Grinsztejn,, R. Haubrich,, J. Lalezari,, A. Mills,, G. Pialoux,, T. Wilkin,, M. Peeters,, J. Vingerhoets,, G. de Smedt,, L. Leopold,, R. Trefiglio, and, B. Woodfall. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370:2938.
148. Maguire, M.,, D. Shortino,, A. Klein,, W. Harris,, V. Manohitharajah,, M. Tisdale,, R. Elston,, J. Yeo,, S. Randall,, F. Xu,, H. Parker,, J. May, and, W. Snowden. 2002. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob. Agents Chemother. 46:731738.
149. Maitland, D.,, G. Moyle,, J. Hand,, S. Mandalia,, M. Boffito,, M. Nelson, and, B. Gazzard. 2005. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 19:11831188.
150. Mallal, S.,, D. Nolan,, C. Witt,, G. Masel,, A. M. Martin,, C. Moore,, D. Sayer,, A. Castley,, C. Mamotte,, D. Maxwell,, I. James, and, F. T. Christiansen. 2002. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727732.
151. Mallal, S.,, E. Phillips,, G. Carosi,, J. M. Molina,, C. Workman,, J. Tomazic,, E. Jagel-Guedes,, S. Rugina,, O. Kozyrev,, J. F. Cid,, P. Hay,, D. Nolan,, S. Hughes,, A. Hughes,, S. Ryan,, N. Fitch,, D. Thorborn, and, A. Benbow. 2008. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358:568579.
152. Marcelin, A. G.,, B. Masquelier,, D. Descamps,, J. Izopet,, C. Charpentier,, C. Alloui,, G. Peytavin,, M. Lavignon,, P. Flandre, and, C. Vincent. 2007. Mutations associated with response to boosted tipranavir in HIV-1-infected PI-experienced patients, abstr. 612. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
153. Marcelin, A. G.,, C. Dalban,, G. Peytavin,, C. Lamotte,, R. Agher,, C. Delaugerre,, M. Wirden,, F. Conan,, S. Dantin,, C. Katlama,, D. Costagliola, and, V. Calvez. 2004. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 48:46874692.